NANOMICRO(SH:688690)2022-03-10 16:00Financial Performance - The company's revenue for 2021 reached RMB 44,634.68 million, representing a 117.74% increase compared to RMB 20,499.29 million in 2020 [28]. - Net profit attributable to shareholders for 2021 was RMB 18,808.97 million, up 158.75% from RMB 7,269.28 million in 2020 [28]. - The net profit after deducting non-recurring gains and losses was RMB 17,215.87 million, reflecting a 172.09% increase from RMB 6,327.29 million in 2020 [28]. - The net cash flow from operating activities for 2021 was RMB 15,756.39 million, an increase of 118.21% compared to RMB 7,220.84 million in 2020 [28]. - The total assets at the end of 2021 amounted to RMB 127,953.11 million, a 99.97% increase from RMB 63,984.80 million at the end of 2020 [28]. - The net assets attributable to shareholders reached RMB 104,226.41 million, up 94.77% from RMB 53,512.28 million at the end of 2020 [28]. - Basic earnings per share for 2021 were RMB 0.4974, a 143.70% increase from RMB 0.2041 in 2020 [28]. - The weighted average return on equity for 2021 was 23.84%, an increase of 9.17 percentage points from 14.67% in 2020 [28]. Dividend and Capital Management - The proposed cash dividend for the 2021 fiscal year is CNY 0.71 per 10 shares, totaling CNY 28,410,362.31, which represents 15.10% of the net profit attributable to shareholders [7]. - The company does not plan to increase capital reserves or issue bonus shares [7]. - The audit report issued by Rongcheng Accounting Firm is a standard unqualified opinion [6]. Corporate Governance and Compliance - The board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report [4]. - The company has no non-operating fund occupation by controlling shareholders or related parties [9]. - The company has no violations of decision-making procedures for external guarantees [11]. - The company has not disclosed any special arrangements for corporate governance [8]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a substantive commitment to investors [8]. Market and Product Development - The company is focused on expanding its market presence and enhancing its product offerings in the IVD and LCD sectors [22]. - The company plans to continue investing in new product development and technology advancements to drive future growth [22]. - The company's operating revenue for the reporting period increased by 117.74% year-on-year, reaching 446.35 million RMB, driven by the high prosperity of the Chinese biopharmaceutical industry and over a decade of accumulation in drug separation and purification [39]. - Revenue from the biopharmaceutical sector reached 390.24 million RMB, a 134.17% increase year-on-year, accounting for 87.43% of total revenue [40]. - The company developed new products including high-performance reverse-phase silica gel chromatography fillers and mixed-mode ion exchange media, meeting market demands for high standards and efficiency [41]. Research and Development - The company achieved a 98.65% year-on-year increase in R&D expenses, totaling 66.1 million yuan, due to the expansion of the R&D team and increased investment in research activities [84]. - The total R&D expenditure accounted for 14.81% of operating revenue, a decrease of 1.42 percentage points compared to the previous year [83]. - The company has filed 16 new invention patents and received 8 new authorizations during the reporting period, contributing to a cumulative total of 97 applications and 30 authorizations [82]. - The company has developed a comprehensive range of chromatography media, including silica gel and polymer-based materials, to meet diverse customer needs in small and large molecule separation and purification [99]. Risks and Challenges - The company faces risks related to the potential theft of proprietary technologies, which could undermine its competitive advantage in the chromatography media market [107]. - The company is exposed to risks from reliance on single suppliers for raw materials, which could impact production and sales if supply issues arise [109]. - Increased competition from multinational companies and domestic peers in the chromatography media market poses a challenge to the company's market position and growth objectives [112]. Strategic Initiatives - The company plans to enhance its sales team and application technology to increase coverage and service depth for target customers [113]. - The company is closely monitoring industry policies and adjusting its strategies to mitigate risks associated with regulatory changes [120]. - The company aims to provide customized chromatographic materials and solutions during the early R&D stages of biopharmaceutical products, enhancing customer engagement [63]. Management and Remuneration - The total pre-tax remuneration for the chairman and general manager, Jiang Biwang, was CNY 250.54 million for the reporting period [181]. - The total pre-tax remuneration for the financial director and board secretary, Zhao Shun, was CNY 241.74 million for the reporting period [181]. - The total pre-tax remuneration for the deputy general manager and core technical personnel, Chen Rongji, was CNY 246.75 million for the reporting period [181].